Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Update

Aldeyra Therapeutics, Inc (NASDAQ:ALDXGet Free Report) saw a significant growth in short interest in December. As of December 31st, there was short interest totalling 3,840,000 shares, a growth of 8.2% from the December 15th total of 3,550,000 shares. Based on an average daily volume of 463,300 shares, the short-interest ratio is currently 8.3 days.

Aldeyra Therapeutics Trading Up 1.3 %

Shares of Aldeyra Therapeutics stock traded up $0.06 during mid-day trading on Friday, hitting $4.84. 274,810 shares of the stock were exchanged, compared to its average volume of 370,307. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80. The company has a 50-day simple moving average of $4.94 and a 200 day simple moving average of $4.97. Aldeyra Therapeutics has a 12 month low of $2.71 and a 12 month high of $6.55.

Aldeyra Therapeutics (NASDAQ:ALDXGet Free Report) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share for the quarter, hitting the consensus estimate of ($0.25). On average, sell-side analysts forecast that Aldeyra Therapeutics will post -0.92 earnings per share for the current fiscal year.

Institutional Trading of Aldeyra Therapeutics

A number of large investors have recently added to or reduced their stakes in ALDX. Perceptive Advisors LLC grew its position in shares of Aldeyra Therapeutics by 7.9% during the 2nd quarter. Perceptive Advisors LLC now owns 9,275,851 shares of the biotechnology company’s stock valued at $30,703,000 after acquiring an additional 682,265 shares during the period. Federated Hermes Inc. purchased a new position in Aldeyra Therapeutics in the 2nd quarter valued at approximately $1,758,000. Jacobs Levy Equity Management Inc. grew its position in shares of Aldeyra Therapeutics by 163.4% in the third quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock valued at $2,571,000 after purchasing an additional 295,864 shares in the last quarter. International Assets Investment Management LLC boosted its stake in Aldeyra Therapeutics by 397.0% in the 3rd quarter. International Assets Investment Management LLC now owns 287,287 shares of the biotechnology company’s stock worth $15,480,000 after purchasing an additional 229,487 shares during the period. Finally, Barclays PLC grew its holdings in Aldeyra Therapeutics by 280.1% during the 3rd quarter. Barclays PLC now owns 65,561 shares of the biotechnology company’s stock valued at $353,000 after buying an additional 48,313 shares in the last quarter. Hedge funds and other institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics Company Profile

(Get Free Report)

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.

See Also

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.